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Background Cardiac resynchronization therapy (CRT) is associated with improved morbidity and mortality in patients with chronic
heart failure (CHF) on optimal medical therapy. The impact of CHF medication optimization followingCRT, however, has
never been comprehensively evaluated. In the current study, we therefore investigated the effect of CHF medication
dosage on morbidity and mortality in CHF patients after CRT implantation.
Methods
and results
Chronic heart failure medication was assessed in 185 patients after CRT implantation. During an overall mean follow-up
of 44.6 months, 83 patients experienced a primary endpoint (death, heart transplantation, assist device implantation,
or hospitalization for CHF). Treatment with higher dosages of angiotensin-converting enzyme inhibitor (ACE-I) or angio-
tensin receptor blockers (ARBs) (P ¼ 0.001) and beta-blockers (P, 0.001) as well as with lower dosages of loop diure-
tics (P, 0.001) was associated with a reduced risk for the primary combined endpoint as well as for all-cause mortality.
Echocardiographic super-responders to CRT were treated with higher average dosages of ACE-I/ARBs (68.1 vs. 52.4%,
P, 0.01) and beta-blockers (59 vs. 42.2%, P, 0.01). During follow-up, the average dosage of loop diuretics was
decreased by 20% in super-responders, but increased by 30% in non-super-responders (P, 0.03).
Conclusion The use of higher dosages of neurohormonal blockers and lower dosages of diuretics is associated with reduced mor-
bidity and mortality following CRT implantation. Our data imply a beneficial effect of increasing neurohormonal blockade
whenever possible following CRT implantation.
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Introduction
Modern treatment of chronic heart failure (CHF) is a multi-modal ap-
proach, with optimal medical therapy and device therapy represent-
ing the cornerstones of management. Cardiac resynchronization
therapy (CRT) is an established treatment for CHF patients with
wide QRS complex and reduced left ventricular (LV) function,
based on the reduction in morbidity and mortality observed in
large-scale clinical trials.1 –5 While these studies overall consistently
demonstrated a significant improvement for CHF patients, the indi-
vidual benefit derived from CRT varies largely.6 Indeed, a significant
number of subjects demonstrate good to excellent response, both
clinically and echocardiographically, whereas others experience
little or no benefit. The reason for the latter are numerous, with
narrow QRS width and the lack of left bundle branch block being
most consistently associated with failure to respond.7
The other pivotal pillar of modern heart failure therapy is optimal
medical management, which can be challenging in these highly fragile
patients. Several classes of drugs reduced morbidity and mortality in
large-scale clinical trials, including angiotensin-converting enzyme
inhibitors (ACE inhibitors),8– 10 angiotensin receptor blockers
(ARBs),11,12 beta-blockers,13–15 and aldosterone antagonists,16,17
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which is why they are routinely used in these individuals. Indeed, CRT
is only indicated in CHF patients with severely reduced LV function
who already are on ‘optimal medical therapy’ and remain symptom-
atic.18 However, CHF patients do not always tolerate maximal doses
of one or all of these important medications. As a result, optimal
medical therapy has been defined as the individually tolerated
maximum dose of CHF medication, which needs to be established
before CRT implantation can be considered.19
Once a CRT device has been implanted, however, this situation
may change, particularly in patients with a pronounced improvement
in LV function on echocardiography. Yet, a large prospective study
(IMPROVE-HF) recently demonstrated that doses of evidence-based
medication used in CHF patients after CRT implantation were signifi-
cantly lower than those used in clinical trials.20 Another small-scale
preliminary study suggested that failure to adapt heart failure medica-
tion after CRT is associated with a worse outcome.21
Until today, however, the pattern of adaptation of CHF medication
as well as its impact on hard clinical endpoints following CRT
implantation has not been comprehensively examined. In the
current study, we therefore investigated the association of CHF
medication dosage on morbidity and mortality in a large cohort of
CHF patients after CRT implantation.
Methods
Study population and device implantation
Our study population consisted of 185 consecutive patients, who under-
went CRT implantation at the University Hospital Zurich, Switzerland,
between February 2000 and December 2010. Only patients for whom
a complete 24-month follow-up with serial clinical assessment was avail-
able or who reached a mortality endpoint prior to this time point were
included. Indication for CRT implantation was based on the Guidelines
of the European Society of Cardiology.18,22 This retrospective study
was approved by the cantonal and national ethic authorities. Patients
were termed as super-responder in case of an improvement in endsysto-
lic volume index (ESVI) ≥40%.
Cardiac resynchronization therapy device implantation was mostly
performed under local anaesthesia following a standard approach. An
LV lead was inserted via a transvenous approach into either a lateral
or posterolateral branch of the coronary sinus whenever possible.
When transvenous lead placement failed, the LV lead was implanted
epicardially. The right atrial and the right ventricular leads were
placed conventionally in the right atrial appendage and the right ven-
tricular apex, respectively. Cardiac resynchronization therapy devices
and leads from Biotronik, Boston Scientific, Medtronic, and St. Jude
Medical were used.
Data acquisition and endpoints
Data were retrospectively obtained from patient files, general practi-
tioners, external cardiologists, and/or other specialists and also by tele-
phone interview with the patient, if necessary. To comprehensively
assess heart failure medication after CRT implantation, we subdivided
the 24-month follow-up period into half-monthly intervals. Medication
dosages were assessed at every time point and calculated as the percent-
ageof the target doseof each individual drug (seeSupplementarymaterial
online, Table S1). Dosages administered for,1 month were counted as a
full month if they were taken longer than 20 days and as half a month, if
administered between 10 and 20 days. If a dose was administered for
,10 days, it was excluded from the calculation. In the end, a mean
dosage was calculated for every drug in every patient over a time
period of 24 months after CRT implantation or until a mortality endpoint
was reached during this time. This overall mean dosage was subsequently
used for statistical analyses. If hospitalization occurred during follow-up,
the medication dosage from hospital admission was recorded. Similarly,
in case of occurrence of a mortality endpoint (death, heart transplant-
ation, and implantation assist device) before the end of the 2-year follow-
up, medication from hospital admission (if available) or from a preceding
medical record was used.
The primary combined endpoint of our study was hospitalization for
heart failure or death (defined as death (from any cause), heart trans-
plantation, or assist device implantation). The secondary endpoint of
the study was death (from any cause), heart transplantation, or ventricu-
lar assist device implantation.
Statistics
Statistical analyses were performed using SPSS 17.0 (SPSS, Inc., Chicago,
IL, USA). The influence of drug dosages on outcome measures was
assessed by univariable and multivariable Cox regression analyses,
adjusting for QRS duration, bundle branch block, baseline LV ejection
fraction (EF), and the respective mediation dosage at baseline. No col-
linearity was observed between the adjusted variables. The proportion-
al hazard assumption was tested using partial residuals and found to be
justified. Cumulative freedom from events for patients with low and
high doses of CHF medication were assessed by the Kaplan–Meier
method and calculated with the log-rank test. Differences between sub-
groups were assessed using Student’s t-test and x2 test for continuous
and categorical variables, respectively. A P-value of,0.05 was consid-
ered significant.
Results
Study population characteristics
Baseline characteristics of our patients before CRT implantation are
summarized in Table 1 and are reflective of a ‘real-world’ heart failure
cohort.6,23 The mean follow-up after CRT implantation was 44.6
months. During follow-up, 83 patients experienced a primary end-
point including 51 deaths, 5 heart transplantations, 8 assist device
implantations, and 67 hospitalizations for CHF.
Blood pressure values prior to implantation were low and typical
of those found in heart failure populations undergoing CRT implant-
ation.1,4 All patients were seen in our specialized heart failure clinic
prior to implantation, where great care was taken that the
maximum tolerable dose of heart failure medication was installed
in every patient prior to implantation. Systolic blood pressure in
patients with ,50% of maximal dose ACE inhibitor/ARB dosage at
implantation was lower (111.2+ 8.4 vs. 117.2+18 mmHg, P,
0.05), and pro-brain natriuretic peptide (proBNP) levels higher
(4609+4914.2 vs. 2251.4+ 2580.8 mg/L, P, 0.001), indicating
that these were generally sicker patients with more advanced heart
failure unable to tolerate higher dosages. Similarly, patients with
,50% of maximal dose beta-blocker dosage at implantation were
older (64+11 vs. 58.4+ 10.2 years, P, 0.005) and had higher
creatinine (127.4+44.9 vs. 110.8+43 mmol/L, P, 0.05), as
well as proBNP levels (4276.3+4644.4 vs. 1847.1+1967.7 mg/L,
P, 0.005).
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Patient outcome related to the dosage of
heart failure medication during follow-up
Patient outcome differed significantly depending on the dose of CHF
drugs used over the follow-up period (Figures 1 and 2, and Table 2).
Patients with higher doses of ACE-I/ARBs (Figure 1A, P ¼ 0.001)
and beta-blockers (Figure 1B, P, 0.001) had a significantly better
outcome regarding the combined endpoint of death and hospitaliza-
tion for CHF. Conversely, the latter occurred less frequently in
patients on lower doses of loop diuretics (Figure 1C; P, 0.001).
A consistent effect was found regarding the secondary mortality end-
point (death, heart transplantation, or ventricular assist device
implantation; Figure 2). Patients on higher doses of ACE-I/ARBs
(Figure 2A; P ¼ 0.001) and beta-blockers (Figure 2B; P, 0.001) and
also those with lower doses of loop diuretics (Figure 2C) during
follow-up showed a significantly better survival. A similar picture as
for loop diuretics was equally observed for thiazides, both for the
combined endpoint and for all-cause mortality. However, the abso-
lute number of patients with thiazide diuretics was low compared
with the other (classical) heart failure medication, precluding mean-
ingful Kaplan–Meier analyses.
Hazard ratios for univariable and multivariable analyses are pre-
sented in Table 2. On multivariable analysis, the effect of loop diuretic
dosage on the combined endpoint was no longer statistically signifi-
cant—in contrast to its effect on total mortality, which was highly
significant even after multivariable adjustment. No significant associ-
ation was observed between aldosterone antagonist dosage or digi-
talis dosage and freedom from the combined endpoint or survival
(P ¼ n.s., data not shown).
Heart failure medication during follow-up
in CRT super-responders
Echocardiographic follow-up wasavailable in 152 patients. Mean time
from CRT implantation to follow-up echocardiography was
9.4 months. Echocardiographic super-response was defined as an im-
provement in ESVI ≥ 40%, which was the case in 52 (34.2%) patients.
There was a higher percentage of super-responders among females
(48.3 vs. 30.9% in males, P ¼ 0.08) and among patients with non-
ischaemic cardiomyopathy (48.8 vs. 16.9%, P, 00001). Also, both
the end-diastolic (99.6+31 vs. 117.6+41.9 mL/m2, P, 0.01) and
end-systolic volume index (72.9+ 26.5 vs. 90+38.1, P, 0.01)
were lower and EF higher (27.5+ 7.6% vs. 24.5+7%, P, 0.05)
before CRT implantation in super-responders. At baseline, super-
responders were less likely to be on diuretics (65.4 vs. 89%, P,
0.001) and digitalis (7.7 vs. 20.2%, P, 0.05). As expected, super-
responders were significantly less likely to reach the combined end-
point (5-year freedom from the combined endpoint 78.1 vs. 43.2%,
P, 0.01) and the mortality endpoint (86.5 vs. 55.1%. P, 0.01)
than those without an improvement in ESVI ,40% (‘non-super-
responders’).
Medication during the follow-up of super-responders and those
patients without an improvement in ESVI ≤40% (‘non-super-
responders’) are presented in Table 3 and Figure 3. The average
dose of ACE inhibitor/ARB during follow-up was 68.1 and 52.4% of
the maximal dose in super-responders vs. non-super-responders,
respectively (P, 0.01); similarly, the average dose of beta-blocker
was higher in the former vs. the latter (59 vs. 42.2% of maximum
dose, P, 0.01). In contrast, no statistically significant difference
with respect to average dose diuretics or digitalis was seen
between the two groups, although numerical differences were point-
ing in the same direction. Super-responders were more likely to be
on .50% of ACE inhibitor dose than non-super-responders (63.5
vs. 45%, P, 0.05). Conversely, the former were less likely to be
on .10% maximal dose of loop diuretics (17.3 vs. 45%, P, 0.001)
or thiazides (3.8 vs. 15%, P, 0.05). A different cut-off (.10%) was
used for diuretics owing to the fact that very few patients were on
high absolute doses of diuretics.
During follow-up, the dosage of loop diuretics was on average
decreased by 20% in super-responders, whereas it was increased
by 30% on average in non-super-responders (P, 0.03,Table 4). Simi-
larly, the percentage of patients experiencing an increase in loop
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Table 1 Baseline characteristics
Clinical
Men 149/185 (80.5%)
Age at implantation (years) 63.1+11
New implantation 111/185 (60%)
PM upgrade 69/185 (37.3%)
ICD upgrade 4/185 (2.2%)
ICD-CRT implantation 169/185 (91.4%)
Systolic BP at implantation (mmHg) 113.7+18.4
Systolic BP at implantation (mmHg) 70.7+10.5
Heart rate at implantation (beats/min) 72.5+14.1
NYHA Class I 8/185 (4.3%)
NYHA Class II 39/185 (21.1%)
NYHA Class III 129/185 (69.7%)
NYHA Class IV 9/185 (4.9%)
Risk factors
Diabetes mellitus 46/185 (24.9%)
Hypertension 91/185 (49.2%)
Positive family history 62/185 (33.5%)
Smoker 42/185 (22.7%)
Hypercholesterolaemia 84/185 (45.4%)
Coronary artery disease 84/185 (45.4%)
Rhythm
Sinus rhythm 128/185 (69.2%)
Atrial fibrillation 24/185 (13%)
Paced 33/185 (17.8%)
QRS (ms) 158+34.1
Left bundle branch block 109/184 (59.2%)
Echocardiography
End-diastolic volume index (mL/m2) 112.5+41.9
End-systolic volume index (mL/m2) 84.7+36.1
Ejection fraction (%) 25.7+7.6
RV/RA pressure gradient (mmHg) 32.4+11.1
PM, pacemaker; ICD, implantable cardioverter-defibrillator; CRT, cardiac
resynchronization therapy; BP, Blood pressure; NYHA, New York Heart
Association; RV/RA, Right ventricular/right atrial pressure gradient.
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diuretics (17.3 vs. 49%, P, 0.001) or thiazides (0 vs. 12%, P, 0.01)
was lower in super-responders vs. non-super-responders.
Discussion
In the current study, we found that the use of higher dosages of neu-
rohormonal blockers and lower dosages of diuretics is associated
with reduced morbidity and mortality after CRT implantation. Fur-
thermore, we demonstrate that super-responders to CRT were
treated with higher doses of ACE inhibitor/ARB and beta-blockers,
but with lower doses of loop diuretics following CRT implantation.
To the best of our knowledge, this is the first study to comprehen-
sively assess the effect of different doses of contemporary heart
failure medication on clinical outcomes in CRT patients. Our findings
raise several important issues regarding the medical management of
these patients.
Effect of renin–angiotensin–aldosterone
system blockade
Over the last 25 years, numerous pivotal trials have established the
role of neurohormonal blockade in CHF patients to improve morbid-
ity and mortality. Indeed, ACE inhibitors were demonstrated to lead
to improve the clinical outcome in several landmark trials including
CONSENSUS, SOLVD, and SAVE.8– 10 Later, ARBs were found to
be similarly effective, especially in patients intolerant to ACE inhibi-
tors.11,12 Further studies have suggested an increasing benefit with
higher dosages of neurohormonal blockade. In the Assessment of
Treatment with Lisinopril And Survival (ATLAS) trial, patients on
Figure 1 Freedom from the combined endpoint for patients with high (≥median, grey) dosage and low (,median, black) dosage of angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker (A), beta-blockers (B), and loop diuretics (C) during the first 24 months after cardiac
resynchronization therapy (CRT) implantation.
Figure2 Freedom from death for patients with high (≥median, grey) dosage and low (,median, black) dosage of angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker (A), beta-blockers (B), and loop diuretics (C) during the first 24 months after CRT implantation.
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high-dose lisinopril had a 15% reduced risk of death or CHF hospital-
ization.24 Similar findings have been obtained in the Heart failure End-
point evaluation of Angiotensin II Antagonist Losartan (HEAAL) trial
for ARBs.25 It has therefore been recommended to adjustmedication
dosage to the maximum tolerated dose.19 Of the reasons why ACE-I/
ARBs are not uptitrated, symptomatic hypotension and renal insuffi-
ciency are most frequent. Also in our cohort, patients with ,50%
of maximal dose ACE inhibitor/ARB dosage during follow-up had
significantly higher baseline creatinine (142.6+59.3 vs. 110.7+
34.3 mmol/L, P, 0.0001) and proBNP levels (4598+4251.6 vs.
3039.8+4089.6 mg/L, P, 0.03), indicating more advanced renal
disease in these patients. In addition, subjective symptoms including
dizziness and (pre-) syncope likely contributed to the lack of
further uptitration.
After CRT implantation, a pilot study in 91 patients reported
an improvement in morbidity and mortality with increasing dosages
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Table 3 Medication of super-responders and non-super-responders during follow-up
Total Super-responder Non-super-responder P-value
52/152 (34%) 100/152 (66%)
Average dose (% of maximal dose)
ACE-I/ARB 57.7+34.5 68.1+33.9 52.4+33.7 ,0.01
Beta-blockers 48+37.2 59+42.8 42.2+32.7 ,0.01
Spironolactone 20.5+22.6 20.5+19.7 20.5+24.1 0.94
Loop diuretics 12+14.9 9.6+14.8 13.3+14.9 0.16
Thiazides 3.2+6.1 2.1+4.3 3.7+6.8 0.13
Digitalis 8.8+21 6.2+21.1 10.2+21 0.29
% of Super-responder % of Non-super-responder
% of Patients with .50% (*.10%) dose
ACE-I/ARB 70/152 (46.1%) 31/52 (59.6%) 39/100 (39%) ,0.02
Beta-blockers 48/152 (31.6%) 21/52 (40.4%) 27/100 (27%) 0.09
Spironolactone* 93/152 (61.2%) 35/52 (67.3%) 58/100 (58%) 0.26
Loop diuretics* 54/152 (35.5%) 9/52 (17.3%) 45/100 (45%) ,0.001
Thiazides* 17/152 (11.2%) 2/52 (3.8%) 15/100 (15%) ,0.05
Digitalis* 1/152 (0.7%) 0/52 (0%) 1/100 (1%) 0.47
ACE-I inhibitor, angiotensin-converting enzyme I inhibitor; ARB, angiotensin receptor blocker.
* % of Patients with .50% (*.10%) dose.
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Table 2 Hazard ratios of different heart failure medication dosages during follow-up after CRT implantation
Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
Combined endpoint
Angiotensin-converting enzyme I
inhibitor/angiotensin receptor blocker
0.985 0.978–0.992 ,0.001 0.980 0.970–0.990 ,0.001
Beta-blocker 0.984 0.976–0.991 ,0.001 0.984 0.974–0.994 0.002
Loop diuretics 1.035 1.024–1.046 ,0.001 1.007 0.986–1.029 0.524
Mortality
Angiotensin-converting enzyme I
inhibitor/angiotensin receptor blocker
0.986 0.977–0.994 0.001 0.980 0.969–0.992 0.001
Beta-blocker 0.984 0.976–0.992 ,0.001 0.982 0.971–0.994 0.003
Loop diuretics 1.038 1.025–1.050 ,0.001 1.023 1.005–1.041 0.014
Multivariable analysis adjusted for QRS duration, bundle branch block, baseline left ventricular (LV) ejection fraction (EF), improvement of LVEF, and the respective medication at
baseline. Hazard ratios (HRs) were calculated for every 1% change in average CHF medication over the follow-up period. As such, an HR of 0.985 (univariable analysis for
angiotensin-converting enzyme I inhibitor/angiotensin receptor blocker) indicates an increase in the hazard by 1.52% with every 1% decrease in average dosage of
angiotensin-converting enzyme I inhibitor/angiotensin receptor blocker during follow-up.
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of ACE inhibitors or ARBs.26 This smaller scale preliminary
study, however, only investigated the effect of medication dose at
6 months after CRT implantation and its relationship on subsequent
outcomes, whereas in the current study we integrated drug dosage
over the whole 24 months after implantation. Indeed, the latter is
of critical importance in order to account for the frequent adapta-
tions in CHF medication, which need to be performed in often rela-
tively unstable patients. Our findings are furthermore consistent with
a recent study, in which clinical responders to CRT were more likely
to be on the target dose of ACE inhibitors and beta-blockers when
compared with non-responders.27 This study, however, only investi-
gated the effect on clinical response (improvement in New York
Heart Association class by ≥1), and furthermore only assessed ac-
complishment of target dose in a binary manner; in contrast, we mi-
nutely investigated the effect of drug dosage during follow-up and its
effect both on echocardiographic super-response and on clinical
outcome. The data from our study hence extend these preliminary
findings, demonstrating a statistically significant, dose-dependent de-
crease in morbidity and mortality for increasing dosages of ACE inhi-
bitors (or ARB) with our comprehensive mode of assessment.
Figure 3 Doses of heart failure medication of super-responders (grey) vs. non-super-responders (black). Data are presented as average dose
during follow-up (+standard error of the mean). Super-response was defined as a decrease in ESVI ≥40%.
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Table 4 Medication change in super-responders and non-super-responders over the follow-up
Total Super-responder Non-super-responder P-value
52/152 (34%) 100/152 (66%)
Average fold-increase over 2 years
ACE-I/ARB 1.4+1.6 1.4+1.7 1.3+1.5 0.82
Beta-blockers 1.3+1.1 1.5+1.3 1.2+1.1 0.28
Spironolactone 1+1.4 0.9+1 1.1+1.6 0.50
Loop diuretics 1.1+1.5 0.8+0.8 1.3+1.7 ,0.03
Thiazides 0.3+0.6 0.2+0.4 0.4+0.7 0.19
Digitalis 0.3+1.4 0.3+1.1 0.4+1.5 0.71
% of Super-responder % of Non-super-responder
% of Patients with dose increase
ACE-I/ARB 47/152 (30.9%) 15/52 (28.8%) 32/100 (32%) 0.69
Beta-blockers 64/152 (42.1%) 26/52 (50%) 38/100 (38%) 0.16
Spironolactone 30/152 (19.7%) 8/52 (15.4%) 22/100 (22%) 0.33
Loop diuretics 57/152 (37.5%) 9/52 (17.3%) 48/100 (48%) ,0.001
Thiazides 12/152 (7.9%) 0/52 (0%) 12/100 (12%) ,0.01
Digitalis 8/152 (5.3%) 4/52 (7.7%) 4/100 (4%) 0.33
ACE-I inhibitor, angiotensin-converting enzyme I inhibitor; ARB, angiotensin receptor blocker.
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Aldosterone antagonists are equally established in the treatment
of CHF patients, based on the landmark RALES, EMPHASIS-HF,
and EPHESUS studies.16,17 There are no strong data supporting the
use of higher vs. lower doses of aldosterone antagonists in heart
failure aside from the general recommendation to employ the
dosages used in the aforementioned landmark trials. Interestingly,
in our cohort, no dose-dependent association with clinical
outcome was observed with aldosterone antagonists. Furthermore,
the dosage of aldosterone antagonists was not higher in super-
responders when compared with non-super-responders. These
findings may be due to the inherent difficulty (and fear) of increasing
aldosterone antagonist dosages due to the risk of hyperkalaemia and
worsening renal function,28 especially on the basis of already estab-
lished and, ideally, maximized ACE inhibitor/ARB therapy.
Effect of beta-blocker therapy
In the three pivotal clinical trials investigating the use of beta-blockers
in CHF—Cardiac Insufficiency Bisoprolol Study II (CIBIS II), Carvedi-
lol Prospective Randomized Cumulative Survival (COPERNICUS),
and Metoprolol CR/XL Randomized Intervention Trial in Congestive
Heart Failure (MERIT-HF)—an approximate 34% relative reduction
in mortality was observed in each of the studies.13– 15 Similar to
ACE-inhibitors, treatment with the maximum tolerated dosage is
recommended also for beta-blockers in CHF patients.19 Patients
with ,50% of maximal beta-blocker dosage during follow-up in
our cohort were older (64.8+ 11.3 vs. 60+10 years, P, 0.005)
and had higher baseline creatinine (131.1+ 54.4 vs. 112.3+
35.2 mmol/L, P, 0.02) and proBNP levels (4512.5+ 4547.6 vs.
2294.6+ 3155.6 mg/L,P, 0.002), indicating that theyweregeneral-
ly sicker and unable to tolerate higher dosages. In addition, similar to
ACE-I/ARBs, subjective symptoms including dizziness and (pre-)
syncope likely prohibited further uptitration.
In patients after CRT implantation, the complete lack of beta-
blocker therapy has been shown to be associated with increased
mortality.29 Similarly, in the smallCARIBE-HF trial, 15patients receiv-
ing a CRTwereable to tolerate higher dosages of beta-blockers com-
pared with 69 patients without CRT.30 The effect of beta-blocker
dosing on outcomes after CRT, however, has so far not been ad-
equately assessed. The impressive dose-dependent reduction in
mortality associated with increasing beta-blocker dosage observed
in our study, hence, represents an important piece of guidance for
medical therapy after CRT implantation. The fact that this effect
was highly significant and independent of potential clinical and echo-
cardiographic confounders appears to support the importance of
attempting to obtain an adequate beta-blocker dosage in these
patients.
Effect of digitalis
There is some ambiguity regarding the effect of digoxin on cardiovas-
cular endpoints, which has been extensively discussed on the basis of
recently published trials and observations and which has not been
finally solved. Most of the evidence supporting the use of digitalis in
CHF patients stems from the DIG trial, in which an effect on morbid-
ity (CHF hospitalization) but not mortality could be demonstrated.31
Several subgroup analyses from other large trials, most prominently
the AFFIRM trial, have equally investigated the effect of digoxin with
partly conflicting results.32,33 The most frequent reason for
prescription of digitalis is advanced heart failure and heart failure
with atrial fibrillation (AF). Indeed, in our cohort, patients on digitalis
had higher proBNP levels at baseline (5332.9+5378.4 vs. 3332.2+
3851 mg/L, P, 0.03) with similar creatinine levels, indicating a more
advanced degree of heart failure; furthermore, digitalis was more fre-
quently used in patients with AF when compared with those without
AF [10 of 24 (41.7%) vs. 22 of 161 (13.7%), P, 0.001].
In our study, we observed no association between the digoxin
dose and outcome. However, more non-super-responders were
still on digitalis during follow-up after CRT, probably reflecting the
reduced clinical state of these patients compared with super-
responders. Indeed, unlike RAAS inhibitors and beta-blockers, an in-
creasing dosage of digitalis is generally not associated with the
improved outcome and may, in fact, cause harm up to digitalis tox-
icity.Also in the long term, an increase in hospitalizations forpotential
digoxin toxicity and arrhythmic mortality and also for higher all-cause
mortality have been reported with higher doses of digoxin.31,34
Effect of diuretics
The effect of diuretics on morbidity and mortality has not been
studied in the same manner as for ACE inhibitors, beta-blockers, or
aldosterone antagonists. It is known that volume overload and con-
gestion is the leading causeof hospitalization in acute decompensated
heart failure, which is why the primary use of diuretics lies in the
symptomatic treatment to reach and maintain the patient’s ‘dry
weight’.18 Consequently, in our study, CRT super-responders were
less likely to be treated with diuretics, and if so required smaller
doses. This is consistent with previous studies, including a subgroup
analysis from the DIG trial, where an increased long-term risk for
mortality and hospitalizations was observed with chronic diuretic
use in CHF patients.35
Interestingly, a higher dosage of loop diuretics was associated with
a higher hazard for the combined endpoint on univariable, but not
multivariable, analysis. These findings indicate that other para-
meters—likely baseline EF and loop diuretic dosage prior to CRT im-
plantation – play an important role regarding subsequent CHF
hospitalization. Nevertheless, higher dosages of loop diuretics
were associated with a worse outcome regarding total mortality
even after adjusting for these factors. Our overall data are consistent
with several other observational studies, which illustrated a worse
outcome in patients with advanced heart failure on higher doses of
diuretics.36,37 The present study’s results hence extend these previ-
ous observations to CHF patients after CRT implantation. Just like
our data, however, these studies are unable to answer the question
whether adverse outcomes in patients on higher doses of diuretics
are reflective of the impaired clinical condition in these patients or
whether, conversely, diuretic use in higher doses may in itself have
a negative impact on mortality. This aspect will hence require
further study to clarify.
Improved outcome with optimized
chronic heart failure medication after
cardiac resynchronization therapy—a
causality conundrum
Our data indicate that an improvement in medical therapy (increase
in neurohormonal blockade and decrease in diuretics use) is
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associated with improved morbidity and mortality after CRT. Our
results further demonstrate that super-responders to CRT are
treated with higher doses of both ACE inhibitors/ARBs and beta-
blockers, whereas loop diuretics are more likely to be decreased in
super-responders and increased in non-super-responders. One of
the obvious questions about our findings is whether increased neu-
rohormonal blockade is a result of response to CRT (and the result-
ing possibility to increase the dose of these medications) or,
conversely, LV reverse remodelling and improved clinical outcome
are a result of the increase in neurohormonal blockade. By virtue
of its retrospective nature, our study cannot answer this question
on a causal basis. However, some aspects of our data imply a combin-
ation of the two to be operative.
A very small preliminary study in 30 patients previously demon-
strated the lackofoptimal medical therapyatbaseline tobeassociated
with less pronounced reverse remodelling after CRT.38 In our study,
however, great care was taken that patients only undergo CRT im-
plantation if they are truly on optimal medical therapy prior to im-
plantation, i.e. on the maximum tolerated dose of heart failure
medication. Furthermore, the effect of drug dosage during follow-up
appeared independently associated with the clinical outcome even if
adjusted for the respective baseline dosage. An increase during
follow-up is hence likely the result of response to CRT, and not the
other way around.
By restoring both mechanical and, probably more importantly,
electrical synchronicity, CRT leads to an improvement in heart
failure symptoms and blood pressure.39 As a result of this, patients
responding toCRT may tolerate an increase in neurohormonal block-
adeduring follow-up,whichhadbeenpreventeddue to theaforemen-
tioned reasons prior to CRT. Increased beta-blocker dosage and also
ACE inhibitor/ARB dosage appeared independently associated with
an improved outcome in our study, even if adjusted for clinical and
echocardiographic parameters at baseline. The direct effect of ACE
inhibitor/ARB therapy on ventricular reverse remodelling (e.g. in-
crease inLVEF)does not appear tobeaspronouncedas that observed
with beta-blockers.18,40–42 Taken together, these findings hence
strongly imply mechanisms other than an improvement in echocar-
diographic parameters to be involved in the beneficial effect of
increased beta-blocker and ACE-I/ARB dosage after CRT.
Limitations
Some differences in baseline parameters are pertinent to our study
cohort which deserves to be commented on. Echocardiographic
LV dysfunction at baseline was worse in non-super-responders
when compared with super-responders. These findings imply that
less sick patients may have had a higher chance of becoming super-
responders to CRT than those who are already past the ‘point of
no return’. A similar observation has recently been made in a large
registry43 and also in a sub-analysis of MADIT-CRT.44 Due to the (ab-
solute) low number of outcome events, correction for only a
selected numberof variableswas feasible for avalidmultivariable ana-
lysis. Great care and efforts were taken to minutely assess medication
status of our patients, enabling calculation of the presented results in-
cluding the association between clinical outcome and echocardio-
graphic super-response. In contrast, analysis of medication change
as a time-dependent co-variable was beyond the scope of our
current study. This retrospective study is finally limited by the fact
that it was restricted to patients with continuous clinical and
mid-term echocardiographic follow-up at our institution, potentially
inducing a selection bias by including only patients from a tertiary re-
ferral centre.However, these aspects are inherent to any ‘real-world’
retrospective analyses from such centres. On the flipside, our data
are representative of broad current day CRT use and should hence
be of a great value for heart failure specialists involved in the care
of these patients. Indeed, in the absence of a randomized clinical
trial on this topic (which is unlikely to be performed), the current
data represent considerable evidence supporting the use of higher
dosages of neurohormonal blockade in CRT patients.
Conclusions
The use of higher doses of neurohormonal blockade and lower doses
of diuretics is associated with reduced morbidity and mortality fol-
lowing CRT implantation. Although our data are, by virtue of their
derivation from a retrospective cohort, only hypothesis generating,
they strongly imply a beneficial effect of increasing neurohormonal
blockade whenever possible following CRT implantation. Our
results hence support this general recommendation from the 2012
ESC heart failure guidelines and extend it to patients after CRT im-
plantation.
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